Therapies / RNAi / Protein / Pharmaceutical / Pharmaceuticals / Pharma / Biology / Biologic / Biological / Genes / Drug / Drugs / Gene / Boston blog main / Boston top stories / National blog main / Wisconsin / Wisconsin blog main / Wisconsin top stories / Alnylam Pharmaceuticals / alpha 1-antitrypsin deficiency / American Association for the Study of Liver Disease / Arrowhead Pharmaceuticals / Biotech / Cardiovascular Disease / clinical trials / Dicerna Pharmaceuticals / FDA / Fibrosis / Hepatitis B / Javier San Martin / Life Sciences / Mani Foroohar / National Organization for Rare Disorders / RNA Interference / SVB Leerink

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Posted on: Sep 16, 2020   |   Posted by: Biotech Mag Top

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

An Arrowhead Pharmaceuticals drug for a rare liver disease now has early Phase 2 results and the data so far look good. Not only did the therapy reduce levels of a mutant...

Continue reading ...